Hainan Poly Pharm Gains MHRA Approval to Sell Generic Immune Dysfunction Drug in UK
Tang Shihua
/SOURCE : Yicai
Hainan Poly Pharm Gains MHRA Approval to Sell Generic Immune Dysfunction Drug in UK

(Yicai Global) Aug. 29 – The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the sale of ganciclovir sodium injection, a generic drug for the treatment of immune dysfunction made by China's Hainan Poly Pharm Co. [SHE:300630], in the UK, the firm said at a press briefing.

The development will have a positive impact on the company's expansion into the European market, Poly Pharm said.

The drug, held by the UK's Kensington Pharma Ltd., which is for the treatment of cytomegalovirus retinitis in patients with immune impairment (including AIDS patients) and for the prevention of CMV infection that may occur in recipients of organ transplants.

Ganciclovir sodium Injection was first approved for sale in the UK in June 1988 by Roche AG (Roche) under the trade name of Cymevene, and has since been sold worldwide.

Follow Yicai Global on
Keywords: UK , MHRA , Poly Pharm